By 2030, an estimated 1.4 billion individuals will be the beneficiaries of hip, knee and shoulder implants. Unfortunately, approximately 7% of these implants require revisions and replacement resulting in a substantial burden for both patients and healthcare providers. The surgical process of revising implants is a complex, challenging, high cost procedure.
In collaboration with a team of expert revision surgeons, Utrecht University Medical Centre and guided by NLC, the European Healthcare Venture Builder, Amotio has secured an exclusive licensing agreement to lead the product development and market entry. Now in its pre-seed funding phase, the company is seeking strategic investors.
Amotio offers an innovative, patented approach for improved implant revision surgery by developing unique bone cement removal devices, integrated with advanced patient specific 3D surgical planning and printing technology. The aim is to set a new standard for excellence in cemented implant revision surgery through reducing complexity and trauma of surgery and reduce the rehabilitation and time to recovery whilst reducing significant costs to the healthcare provider.
The new devices have completed early concept testing and market evaluation. The next stage is to enter a robust product development and clinical evaluation process to enable medical device registration in the key global markets and prepare commercial launch in key target markets.
Meet the team
Taco van der Feltz
Taco joined NLC in 2015 and is a highly international and networked entrepreneur trained as Medical Doctor and Medical Biologist. He is a visionary strategist conversant within and across disciplines. As Venture Partner, Taco focuses on building innovative companies and strengthening NLC’s abilities to bring innovations to healthcare.
CEO - Amotio